Galectin Therapeutics (GALT) Competitors $4.10 +0.22 (+5.67%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$4.02 -0.08 (-1.95%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GALT vs. VERV, LENZ, PRAX, RCUS, AVXL, GPCR, SYRE, AKBA, PHAR, and CRONShould you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include Verve Therapeutics (VERV), LENZ Therapeutics (LENZ), Praxis Precision Medicines (PRAX), Arcus Biosciences (RCUS), Anavex Life Sciences (AVXL), Structure Therapeutics (GPCR), Spyre Therapeutics (SYRE), Akebia Therapeutics (AKBA), Pharming Group (PHAR), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry. Galectin Therapeutics vs. Its Competitors Verve Therapeutics LENZ Therapeutics Praxis Precision Medicines Arcus Biosciences Anavex Life Sciences Structure Therapeutics Spyre Therapeutics Akebia Therapeutics Pharming Group Cronos Group Verve Therapeutics (NASDAQ:VERV) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Which has more risk & volatility, VERV or GALT? Verve Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Do institutionals and insiders hold more shares of VERV or GALT? 97.1% of Verve Therapeutics shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 19.3% of Verve Therapeutics shares are owned by insiders. Comparatively, 50.1% of Galectin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor VERV or GALT? In the previous week, Galectin Therapeutics had 9 more articles in the media than Verve Therapeutics. MarketBeat recorded 9 mentions for Galectin Therapeutics and 0 mentions for Verve Therapeutics. Galectin Therapeutics' average media sentiment score of 0.63 beat Verve Therapeutics' score of 0.00 indicating that Galectin Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Verve Therapeutics Neutral Galectin Therapeutics Positive Is VERV or GALT more profitable? Galectin Therapeutics has a net margin of 0.00% compared to Verve Therapeutics' net margin of -303.64%. Galectin Therapeutics' return on equity of 0.00% beat Verve Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Verve Therapeutics-303.64% -35.81% -27.57% Galectin Therapeutics N/A N/A -225.32% Do analysts recommend VERV or GALT? Verve Therapeutics presently has a consensus target price of $14.57, suggesting a potential upside of 30.92%. Galectin Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 46.34%. Given Galectin Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Galectin Therapeutics is more favorable than Verve Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verve Therapeutics 0 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33Galectin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, VERV or GALT? Galectin Therapeutics has lower revenue, but higher earnings than Verve Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerve Therapeutics$32.33M30.69-$198.71M-$2.11-5.27Galectin TherapeuticsN/AN/A-$47.05M-$0.64-6.41 SummaryGalectin Therapeutics beats Verve Therapeutics on 9 of the 15 factors compared between the two stocks. Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GALT vs. The Competition Export to ExcelMetricGalectin TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$248.55M$2.57B$5.76B$9.58BDividend YieldN/A1.67%4.41%4.10%P/E Ratio-6.4122.6131.1026.05Price / SalesN/A550.49432.51103.82Price / CashN/A180.4637.7358.48Price / Book-2.205.939.536.61Net Income-$47.05M$31.83M$3.26B$265.56M7 Day Performance14.85%1.89%2.10%1.97%1 Month Performance45.39%1.33%2.81%-0.36%1 Year Performance77.49%8.84%30.56%19.03% Galectin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GALTGalectin Therapeutics2.2531 of 5 stars$4.10+5.7%$6.00+46.3%+77.5%$248.55MN/A-6.419VERVVerve Therapeutics3.004 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110LENZLENZ Therapeutics1.2811 of 5 stars$38.77+11.8%$49.60+27.9%+80.0%$989.15MN/A-20.41110Gap UpHigh Trading VolumePRAXPraxis Precision Medicines1.7277 of 5 stars$44.95-2.2%$95.22+111.8%-2.0%$966.84M$8.55M-3.66110RCUSArcus Biosciences2.4173 of 5 stars$9.19+1.4%$21.14+130.2%-40.6%$964.27M$258M-2.90500Positive NewsAVXLAnavex Life Sciences3.8959 of 5 stars$11.35+2.4%$44.00+287.7%+55.5%$946.42MN/A-20.6440Analyst ForecastGPCRStructure Therapeutics2.5137 of 5 stars$17.51+7.4%$75.71+332.4%-49.9%$939.42MN/A-16.68136News CoverageSYRESpyre Therapeutics2.905 of 5 stars$15.25+0.6%$53.40+250.2%-29.8%$915.68M$890K-4.4973AKBAAkebia Therapeutics4.0067 of 5 stars$3.35-2.0%$6.75+101.5%+117.0%$906.80M$160.18M-19.70430PHARPharming Group2.4169 of 5 stars$12.10-8.5%$30.00+147.9%+72.3%$906.45M$297.20M-93.08280Gap UpHigh Trading VolumeCRONCronos Group0.7578 of 5 stars$2.67+16.1%N/A+12.6%$882.76M$117.61M53.40450High Trading Volume Related Companies and Tools Related Companies VERV Alternatives LENZ Alternatives PRAX Alternatives RCUS Alternatives AVXL Alternatives GPCR Alternatives SYRE Alternatives AKBA Alternatives PHAR Alternatives CRON Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GALT) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access